(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) Á¦16ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö : 2021-04-09±³À°ÀÏÀÚ : 2021-04-09
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: ·Ôµ¥È£ÅÚ ºÎ»ê Å©¸®½ºÅ»º¼·ë )
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) Á¦16ȸ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Æó¾Ï ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 4 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ï - Àü¹®ÀÇ : 30,000¿ø/ Àü°øÀÇ : 20,000¿ø ´çÀϵî·Ï - Àü¹®ÀÇ : 40,000¿ø/ Àü°øÀÇ : 30,000¿ø (»çȸÀû °Å¸®µÎ±â¿¡ µû¶ó¼ ¿ÀÇÁ¶óÀÎ Âü¼®ÀÚ ÀοøÀ» ¼±Âø¼øÀ¸·Î ¸¶°¨ÇÒ ¿¹Á¤/ »çȸÀû °Å¸®µÎ±â ´Ü°è¿¡ µû¶ó ÃßÈÄ º¯µ¿ °¡´É)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ëI 13:20~13:50 ¡°New Treatment Option for NSCLC: 3rd generation TKI (Lazertinib)¡± ÀÌÀçö(¿ï»êÀÇ´ë)
ÈÞ½Ä 04¿ù 09ÀÏ 13:50~14:10 Refreshment ()
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 14:10~14:40 Session I: Standard Treatment of Lung Cancer-1. Small Cell Lung Cancer ±è¹ÌÇö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 14:40~15:10 Session I: Standard Treatment of Lung Cancer-2. Neoadjuvant Treatments in NSCLC ³²Çؼº(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 15:10~15:40 Session I: Standard Treatment of Lung Cancer-3. Adjuvant Treatments in NSCLC ÃÖ¼öÀÎ(°í·ÁÀÇ´ë)
ÈÞ½Ä 04¿ù 09ÀÏ 15:40~16:10 Refreshment ()
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 16:10~16:40 Session II: Recent Progress in Advanced NSCLC-4. Targeted Agents ¹ÚÁö¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 16:40~17:10 Session II: Recent Progress in Advanced NSCLC-5. Anti-VEGF Treatments ¹Ú¼øÈ¿(°è¸íÀÇ´ë)
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë 17:10~17:40 Session II: Recent Progress in Advanced NSCLC-6. 1st Line Treatments with Immune Checkpoint Inhibitors ±èÀº¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04¿ù 09ÀÏ Å©¸®½ºÅ» º¼·ë¥² 17:50~18:30 ¡°The vital role of Biologics in Severe asthma with Type 2 inflammation¡± ÀÌÁø±¹(°¡Å縯ÀÇ´ë)